Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wilms tumor 1 mRNA + interleukin-15 mRNA + interleukin-15 receptor alpha mRNA dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
This is an autologous dendritic cell (DC) vaccine developed by Antwerp University Hospital (UZA). The vaccine consists of patient-derived dendritic cells that have been ex vivo electroporated with messenger RNA (mRNA) encoding the Wilms tumor 1 (WT1) protein, along with mRNA for interleukin-15 (IL-15) and the interleukin-15 receptor alpha (IL-15Rα). WT1 serves as a widely expressed tumor-associated antigen, while the co-expression of IL-15 and IL-15Rα is designed to facilitate the trans-presentation of IL-15 to neighboring immune cells. This mechanism aims to enhance the activation, survival, and proliferation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment, thereby mounting a more robust anti-tumor immune response. It is primarily being investigated for advanced solid tumors, including pancreatic, esophageal, liver, and ovarian cancers.
- Other names
- WT1 mRNA-electroporated dendritic cell vaccine with IL-15 and IL-15Rα mRNA
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on wilms tumor 1 mRNA + interleukin-15 mRNA + interleukin-15 receptor alpha mRNA dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wilms tumor 1 mRNA + interleukin-15 mRNA + interleukin-15 receptor alpha mRNA dendritic cell vaccine.